General Information of Drug (ID: DM6M8O4)

Drug Name
SAR440234 Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1/2 [1]
leukaemia 2A60-2B33 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DM6M8O4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [3]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [4]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [5]
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [6]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [7]
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [8]
Otelixizumab DMFNDBC Type-1 diabetes 5A10 Phase 2 [9]
Plamotamab DMOV28A Diffuse large B-cell lymphoma 2A81 Phase 2 [10]
Odronextamab DMP6NVV B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [11]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tagraxofusp DM9HQ5U Acute myeloid leukaemia 2A60 Approved [13]
CD123/CLL1 CAR-T Cells DM45Z3P Acute myeloid leukaemia 2A60 Phase 2/3 [14]
Talacotuzumab DMARVFG Acute myeloid leukaemia 2A60 Phase 2 [15]
MB-102 DMLPNVS Acute kidney injury GB60 Phase 2 [15]
Flotetuzumab DMVR6OM Acute biphenotypic leukaemia 2B33.4 Phase 2 [15]
4SCAR19 and 4SCAR123 DMYPQT4 B-cell lymphoma 2A86 Phase 1/2 [16]
CD123-specific gene-engineered T cells DMHOWU5 Acute myeloid leukaemia 2A60 Phase 1/2 [17]
CART-123 cells DM0MCTJ Acute myeloid leukaemia 2A60 Phase 1/2 [18]
CART-123 cells DM0MCTJ Acute myeloid leukaemia 2A60 Phase 1/2 [19]
Anti-CD123-CAR-transduced T cells DMFV6TY leukaemia 2A60-2B33 Phase 1/2 [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 3 receptor alpha (IL3RA) TTENHJ0 IL3RA_HUMAN Not Available [2]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Not Available [2]

References

1 ClinicalTrials.gov (NCT03594955) First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome. U.S. National Institutes of Health.
2 Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
5 Clinical pipeline report, company report or official report of Genmab.
6 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
7 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
8 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
9 Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
10 Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
11 Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
12 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
13 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
14 ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
17 ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
18 ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
19 ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
20 ClinicalTrials.gov (NCT02937103) A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies